Uzbekistan begins trial over 65 child deaths linked to contaminated cough syrups

Published On 2023-08-12 10:00 GMT   |   Update On 2023-08-12 10:00 GMT

Tashkent: Uzbekistan began a trial on friday over the deaths last year of 65 children linked to contaminated cough syrups, announcing for the first time a much higher death toll than before.The Central Asian nation had previously reported only 20 deaths linked to the medicines, which were produced by India's Marion Biotech.Among the 21 defendants - who are all Uzbek citizens - are former...

Login or Register to read the full article

Tashkent: Uzbekistan began a trial on friday over the deaths last year of 65 children linked to contaminated cough syrups, announcing for the first time a much higher death toll than before.

The Central Asian nation had previously reported only 20 deaths linked to the medicines, which were produced by India's Marion Biotech.

Among the 21 defendants - who are all Uzbek citizens - are former senior officials who were in charge of licensing imported medicines and executives of a private company that imported and distributed them, Uzbekistan's Supreme Court said in statement.

Charges against them include tax evasion, sale of substandard or counterfeit medicines, abuse of office, negligence, forgery, and bribery.

The Indian regulator has canceled the manufacturing license of Marion Biotech, which had exported the syrups to Uzbekistan, and arrested some of its employees.

Read also: 3 employees of Noida-based Marion Biotech arrested

In December, a legal representative of Marion Biotech said the company regretted the deaths.

Read also: QP Pharmachem asked to stop manufacturing after samples found to be of non-standard quality: Govt




Tags:    
Article Source : Reuters

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News